Transthoracic Needle Biopsies: It's More than Just Hitting the Bull's-eye

Aerts, Joachim

doi:10.1158/1078-0432.ccr-15-1999

Cited by 3 publications

(2 citation statements)

References 9 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Besides the exciting results of the NELSON trial which should stimulate development of a screening strategy in most countries, the widespread use of chest computed tomography scans in the workup of different diseases means a growing number of solitary pulmonary nodules are being found. 2,17,18 At present, no reliable biomarker or imaging technique is available to determine whether a lesion is, or will become, malignant in an individual patient within a clinically meaningful time frame. The implementation of volume doubling time or radiomics to determine whether a lesion is malignant remains unvalidated; pathologic diagnosis based on tissue biopsy is still the gold standard in patients with undetermined nodules.…”

Section: Advances In Diagnostics Clinical Staging and Clinical Progmentioning

confidence: 99%

Early-Stage NSCLC: Advances in Thoracic Oncology 2018

Osarogiagbon¹,

Veronesi

Fang

et al. 2019

Journal of Thoracic Oncology

Self Cite

View full text Add to dashboard Cite

2018 was a banner year for all thoracic oncology, but especially for early-stage NSCLC. Three seminal events occurred in the approximately 18 months from mid-2017 to the end of 2018: in June 2017 at the American Society of Clinical Oncology Annual Meeting a small, relatively unheralded study from Max Diehn's group at Stanford University reported on the use of a novel "cancer personalized profiling by deep sequencing" circulating tumor-DNA technology to identify minimal residual disease in patients after curative-intent radiation or surgery for NSCLC; in April 2018 at the American Association for Cancer Research Annual Meeting, Drew Pardoll presented a small pilot study of 21 patients who had received two doses of preoperative nivolumab; in September 2018, at the 19th World Conference on Lung Cancer, Harry J. De Koning presented the long-awaited results of the Dutch-Belgian Lung Cancer Screening Trial (NELSON). These three seminal studies, along with others which are reviewed in this paper, promise to accelerate our progress towards a world in which lung cancer is identified early, more patients undergo curative-intent treatment that achieves the promised cure, and those at risk for failure after treatment are identified early, when the cancer remains most vulnerable. The day is around the corner when lung cancer is defanged and no longer the worldwide terror it currently is. We herein present an overview of the most recent body of work that moves us inexorably towards that day.

show abstract

Section: Advances In Diagnostics Clinical Staging and Clinical Progmentioning

confidence: 99%

Early-Stage NSCLC: Advances in Thoracic Oncology 2018

Osarogiagbon¹,

Veronesi

Fang

et al. 2019

Journal of Thoracic Oncology

Self Cite

View full text Add to dashboard Cite

show abstract

“…Other robotic systems [18], [19], [20], [21], [22], including recently released commercial lung biopsy systems [23], [24], offer a bronchoscopic approach via intraluminal steerable needles [25], [26]. However, they have low diagnostic yield in peripheral lungs and for lesions smaller than 20mm [27], [28], [29], [30].…”

Section: Related Workmentioning

confidence: 99%

An Open-Source 7-Axis, Robotic Platform to Enable Dexterous Procedures within CT Scanners

Schreiber

Shak²,

Norbash³

et al. 2019

2019 IEEE/RSJ International Conference on Intelligent Robots and Systems (IROS)

View full text Add to dashboard Cite

This paper describes the design, manufacture, and performance of a highly dexterous, low-profile, 7 Degreeof-Freedom (DoF) robotic arm for CT-guided percutaneous needle biopsy. Direct CT guidance allows physicians to localize tumours quickly; however, needle insertion is still performed by hand. This system is mounted to a fully active motion stage superior to the patient's head and teleoperated by a radiologist. Unlike other similar robots, this robot's fully seriallink approach uses a unique combination of belt and cable drives for high-transparency and minimal-backlash, allowing for an expansive working area and numerous approach angles to targets, all while maintaining a small in-bore cross-section of less than 16cm 2 . Simulations verified the system's expansive collision free work-space and ability to hit targets across the entire chest, as required for lung cancer biopsy. Targeting error was on average < 1mm on a teleoperated accuracy task, illustrating the system's sufficient accuracy to perform biopsy procedures. While this system was developed for lung biopsies, it can be easily modified for other CT-guided needle based procedures. Additionally, this system is open-hardware. 1 †

show abstract